Portfolio News – Page 12 – The Column Group

Skip to content

Home
Team
Portfolio
News
- TCG News
- Portfolio News
Careers
Contact

Menu

Home
Team
Portfolio
News
- TCG News
- Portfolio News
Careers
Contact

PORTFOLIO NEWS

Accent Therapeutics Bolsters Leadership Team with Key Executive Hires

September 21, 2023

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

September 19, 2023

Eikon Therapeutics Announces Business Update Highlighting Pipeline and Clinical Development Progress ‍

September 11, 2023

Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics

September 7, 2023

Nura Bio Initiates Phase I Clinical Trial for its Oral, Brain-Penetrant SARM1 Inhibitor, NB-4746

August 25, 2023

RAPT Therapeutics Reports Second Quarter 2023 Financial Results

August 11, 2023

ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates

August 10, 2023

Surrozen Provides Second Quarter 2023 Financial Results

August 9, 2023

Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

August 9, 2023

Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress

August 8, 2023

« Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »

The Column Group

Copyright © 2024. The Column Group | Privacy Policy | Terms of Use
Website developed by CP Communications

Scroll to Top